Balloon Aortic Valvuloplasty Market is expected to reach US$ 190.27 Million by 2031

PRESS RELEASE BY The Insight Partners 10 Jun 2024

Share this press on

Non-Compliant Balloons Segment to Lead Balloon Aortic Valvuloplasty Market Based on Product Type During 2023–2031

According to our new research study on “Balloon Aortic Valvuloplasty Market Forecast to 2031 – Global Analysis – by Product Type and Geography,” the market was valued at US$ 125.08 million in 2023 and is projected to reach US$ 190.27 million by 2031; it is expected to register a CAGR of 5.4% from 2023 to 2031. Key factors driving the market growth include the rising prevalence of aortic valve stenosis and increasing demand for minimally invasive procedures. However, the high cost of procedures hinders market growth.

Balloon aortic valvuloplasty (BAV) is a minimally invasive procedure that is used to treat patients with aortic valve stenosis. BAV is a reasonably safe procedure with a high success rate. Nonetheless, it is not a permanent solution for aortic valve stenosis. Sometimes, the valve may narrow again, and a repeat procedure becomes necessary, thereby contributing to the growing balloon aortic valvuloplasty market size.

Balloon Aortic Valvuloplasty Market, by Region, 2023(%)

Balloon Aortic Valvuloplasty Market, by Region, 2023(%)

Balloon Aortic Valvuloplasty Market Size, Growth, Share by 2031

Download Free Sample

Balloon Aortic Valvuloplasty Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Non-Compliant Balloons and Semi-Compliant Balloons) and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

Source: The Insight Partners Analysis

Balloon Aortic Valvuloplasty Market Analysis Based on Segmental Evaluation:

Based on product type, the balloon aortic valvuloplasty market is bifurcated into non-compliant balloons and semi-compliant balloons. In 2023, the non-compliant balloons segment held a significant balloon aortic valvuloplasty market share and is expected to register a higher CAGR in the market during 2023–2031. Non-compliant balloons are high-pressure balloons that are commonly made of polyester or nylon. These balloons have compliance ranging from 1.05–1.10. Non-compliant balloons expand uniformly over their longitudinal axis and usually cannot be expanded beyond a predetermined maximum diameter. The increase in diameter of a non-compliant balloon is up to 110% of the nominal size. These balloons are used for procedures in which the balloon needs to expand to a particular diameter and exert high pressure to open a blockage or dilate the vessel. Therefore, the non-compliant balloons offer the advantage of deforming in a more predictable and stable manner during inflation than semi-compliant ones. Thus, the above-mentioned factors positively influence the overall growth of the balloon aortic valvuloplasty market.

The scope of the balloon aortic valvuloplasty market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In terms of revenue, Europe dominated the balloon aortic valvuloplasty market share in 2023. The rising prevalence of valvular diseases and the growing preference for minimally invasive surgeries are the key factors driving the balloon aortic valvuloplasty market in Europe. Cardiovascular diseases continue to increase and are still among the leading causes of death in Germany. The incidence of heart valve disease progresses immensely with age. Aortic stenosis is a common valvular heart disease with a dismal prognosis when untreated. TAVI or SAVR is recommended in such conditions. TAVI is a standard treatment for aortic valve stenosis in the country.

As per a study titled “Healthcare provision of transcatheter aortic valve implantation in Germany,” published in 2023, a total of 26,506 TAVI procedures were performed in 2021. Compared to 2021, an increase of 4,673 TAVI procedures is expected by 2035. Moreover, based on a longtime voluntary registry founded by the German Society for Thoracic and Cardiovascular Surgery in 1980, well-defined data of all thoracic, cardiac, and vascular surgical procedures performed in 78 German heart surgery departments during 2022 were analyzed. A total of 93,913 heart surgical procedures were performed in 2022. Of these, 38,492 heart valve procedures were performed, including 14,852 isolated heart valve procedures performed as single, 2,880 as double, and 296 as triple valve procedures. In addition, about 20,272 transcatheter heart valve procedures were carried out. Focusing on the distribution of aortic valve procedures for 2022, 17,818 TAVI and 7,798 SAVRs were reported to the registry.

The FRANCE-TAVI Registry published an updated report of trends and evolution of TAVR in the French cohort in 2022. About 85,000 patients were enrolled, with an average age of 83 years. The number of procedures increased from 1,556 in 2010 to 14,114 in 2021. However, the use of TAVR is mainly restricted to those at high risk and remains uncommon in young patients in the country. According to the “Association of Age and Sex with Use of Transcatheter Aortic Valve Replacement in France,” published in 2023, a total of 107,397 patients underwent an isolated aortic valve replacement (59.1% TAVR, 40.9% SAVR). In patients aged 65 years and above, the proportion of TAVR increased by 63.2% from 2015 to 2020.

The balloon aortic valvuloplasty market in the UK is likely to grow due to the rising number of people suffering from valvular diseases and the growing geriatric population who are more susceptible to valvular diseases. According to a study published by Age UK—a registered charity in the UK—in 2020, there were ~12 million people aged 65 and above in the UK. It is estimated that the number of centenarians living in the UK will be 21,000 or more, and one in five people will be aged 65 and above by 2030. As per the research study titled “Uncovering the treatable burden of severe aortic stenosis in the UK,” published in 2021 in the open-access journal Open Heart, ~300,000 people have aortic valve stenosis, a potentially deadly heart condition in the UK. Of the people with aortic stenosis, ~199,000 (68%) had severe aortic stenosis disease. Of these, 172,859 patients with severe aortic stenosis succumbed to death in 2024. The UK population's need for aortic stenosis treatment rises as the population ages. According to the European Heart Journal, about 1.5 million people in the UK aged 65 or over suffered from heart valve disease, including aortic stenosis, in 2015. The number is projected to double by 2046 and reach 3.3 million by 2056.

Initiatives undertaken by French government organizations to enhance awareness regarding valve replacement surgeries support balloon aortic valvuloplasty market growth. The European Association of Percutaneous Cardiovascular Interventions launched the Valve for Life initiative in 2015 to address the gap in heart valve disease care in Europe. The goal was to achieve a 20% improvement in the treatment of severe heart valve disease in 2020 by involving doctors, policymakers, and healthcare authorities to encourage the implementation of life-saving procedures. The program was trialed in France, Poland, and Portugal, where it led to a measurable increase in life-saving interventions for patients. In order to raise the understanding of heart valvular disease, various organizations are working toward making people more aware and funding research projects, favoring the balloon aortic valvuloplasty market growth. Heart Valve Voice is a heart valve disease community benefit organization based in the UK. It works with patients and clinicians to promote awareness regarding heart valve disease and improve diagnosis and treatment methodologies. It involves a group of people with real-life experiences of heart valve disease; it also includes cardiologists and cardiac surgeons, cardiac patient societies, and patients. Similarly, the British Heart Foundation raises funds to research cures and treatments for heart and circulatory diseases, including heart valve disease. Thus, improvements in TAVI combined with research and development are projected to bring new balloon aortic valvuloplasty market trends in the coming years.

B Braun SE; TT Medical, Inc.; Balton; Becton Dickinson and Co; Edwards Lifesciences Corp; Balt; Venus MedTech HangZhou Inc.; NuMED; simeks; and OSYPKA are among the leading companies profiled in the balloon aortic valvuloplasty market report.

Based on product type, the market is bifurcated into non-compliant balloons and semi-compliant balloons. Geographically, the balloon aortic valvuloplasty market is categorized into North America (Canada and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Phone: +1-646-491-9876
Email Id:

Download Free PDF Brochure